Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Donor IL-17 receptor A regulates LPS-potentiated acute and chronic murine lung allograft rejection
Tatsuaki Watanabe, … , Shaf Keshavjee, Tereza Martinu
Tatsuaki Watanabe, … , Shaf Keshavjee, Tereza Martinu
Published November 8, 2023
Citation Information: JCI Insight. 2023;8(21):e158002. https://doi.org/10.1172/jci.insight.158002.
View: Text | PDF
Research Article Pulmonology Transplantation

Donor IL-17 receptor A regulates LPS-potentiated acute and chronic murine lung allograft rejection

  • Text
  • PDF
Abstract

Chronic lung allograft dysfunction (CLAD) is a major complication after lung transplantation that results from a complex interplay of innate inflammatory and alloimmune factors, culminating in parenchymal and/or obliterative airway fibrosis. Excessive IL-17A signaling and chronic inflammation have been recognized as key factors in these pathological processes. Herein, we developed a model of repeated airway inflammation in mouse minor alloantigen-mismatched single-lung transplantation. Repeated intratracheal LPS instillations augmented pulmonary IL-17A expression. LPS also increased acute rejection, airway epithelial damage, and obliterative airway fibrosis, similar to human explanted lung allografts with antecedent episodes of airway infection. We then investigated the role of donor and recipient IL-17 receptor A (IL-17RA) in this context. Donor IL-17RA deficiency significantly attenuated acute rejection and CLAD features, whereas recipient IL-17RA deficiency only slightly reduced airway obliteration in LPS allografts. IL-17RA immunofluorescence positive staining was greater in human CLAD lungs compared with control human lung specimens, with localization to fibroblasts and myofibroblasts, which was also seen in mouse LPS allografts. Taken together, repeated airway inflammation after lung transplantation caused local airway epithelial damage, with persistent elevation of IL-17A and IL-17RA expression and particular involvement of IL-17RA on donor structural cells in development of fibrosis.

Authors

Tatsuaki Watanabe, Stephen C. Juvet, Gregory Berra, Jan Havlin, Wenshan Zhong, Kristen Boonstra, Tina Daigneault, Miho Horie, Chihiro Konoeda, Grace Teskey, Zehong Guan, David M. Hwang, Mingyao Liu, Shaf Keshavjee, Tereza Martinu

×

Figure 11

IL-17RA expression in human CLAD lungs.

Options: View larger image (or click on image) Download as PowerPoint
IL-17RA expression in human CLAD lungs.
Human CLAD allografts from patie...
Human CLAD allografts from patients with repeated pulmonary infection episodes after transplant and control donor lungs are shown. (A) Representative images of immunofluorescence staining for CD45 and IL-17RA of human explanted CLAD lungs and control lungs. Red, CD45; green, IL-17RA. CLAD lung showed IL-17RA staining around airways and vessels. CD45 staining minimally overlapped with IL-17RA. The arrow indicates that IL-17RA costained with CD45. Scale bar: 100 μm. (B) IL-17RA+ staining area over lung section area. IL-17RA+ area in explanted CLAD lungs was trend toward large compared with control donor lungs (P = 0.0519). Mann-Whitney U test. (C–E) Representative pictures of immunofluorescence for IL-17RA, CD45, and α-SMA. (C) Representative immunofluorescence of IL-17RA and CD45. Green, IL-17RA; red, CD45; blue, DAPI. Scale bar: 50 μm. (D) Representative immunofluorescence of IL-17RA and α-SMA. Scale bar: 50 μm. Arrow indicates IL-17RA and α-SMA double-positive staining. Green, IL-17RA; red: α-SMA; blue, DAPI. (E) Representative immunofluorescence of IL-17RA and Collagen. Scale bar: 50 μm. Arrows indicate IL-17RA and Collagen double-positive staining. Green, IL-17RA; red: collagen; blue, DAPI.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts